清毒栓干预宫颈HR-HPV感染局部免疫微环境的实验及临床研究
|
摘要
目的
1.通过检测宫颈上皮内瘤变组织局部免疫微环境相关转录因子T-bet、GATA3、Foxp3的免疫组化表达,从细胞水平探讨宫颈上皮内瘤变病程进展与病变局部免疫微环境中Th1、Th2、Treg细胞数量变化的关系
2.以SiHa宫颈癌细胞上清液、CTL、Treg淋巴细胞共培养体系作为研究对象,观察Treg、清毒栓对CTLA-4、PD-1的蛋白表达的影响,探索Treg细胞在肿瘤免疫逃逸中的机制,探讨中药清毒栓对局部免疫微环境的作用。
3.通过检测清毒栓、安达芬及随诊观察三组经治疗观察3个月后病毒负荷及临床症状积分的变化,判断中药清毒栓的临床疗效。
方法
实验研究：
1.选择经HE染色,病理明确诊断为宫颈炎症及宫颈上皮内瘤变的宫颈组织128例,分为宫颈炎症、CINⅠ级、CINⅡ级及CINⅢ级4组,其中宫颈炎症、CINⅡ级病变组织32例,CINⅠ级34例及CINⅢ级病变组织30例。用免疫组化法检测各组组织中免疫微环境相关转录因子T-bet、GATA3、Foxp3阳性细胞的浸润数量,分析以上三种免疫细胞数量变化与病变进展的关系。
2.CCK-8法测定PBMC生长曲线。
3.用不同浓度SiHa细胞培养上清液作用于CTL细胞及Treg细胞,流式细胞术检测CD8、Treg细胞比例变化。
4.免疫磁珠法分离人外周血CD8+T细胞、Treg细胞,流式细胞术检测分选后细胞的纯度。
5.用CFSE标记法检测淋巴细胞增值,了解Treg细胞对CTL细胞的抑制功能。
6.CCK8法测定各浓度β-榄香烯、清毒栓对CTL细胞增殖的影响。
7.应用Western-Blot检测并比较CTL正常培养组(对照组)、CTL+50%SiHa上清培养组(癌上清组)、CTL+Treg+50%SiHa上清培养组(共培养组)CTL+Treg+50%SiHa上清+8μg/mlβ-榄香烯干预组(β-榄香烯组)、CTL+Treg+50％SiHa上清+2μl/ml清毒栓醇提水沉液组(清毒栓组)五组中CTLA4、PD1的蛋白表达情况。
临床研究
选取北京中医药大学东方医院妇科门诊2009年8月～2011年1月就诊的宫颈HR-HPV感染的患者共90例。随机分成清毒栓治疗组、安达芬对照组、随诊观察组三组进行治疗观察3个月。用HCⅡ检测子宫颈HPVDNA含量(病毒负荷)的变化,判断清毒栓治疗高危型宫颈HPV感染的临床疗效,同时进行临床症状积分统计分析。
结果
1.随着宫颈上皮内瘤变病程的进展,转录因子T-be t阳性的Th1类细胞数量增多,各级病变中Thl类细胞数量变化的差异具有显著性(P<0.05)；转录因子GATA 3阳性的Th2类细胞数量减少,其中宫颈炎症与CINⅠ级病变中细胞数量变化差异不显著(P>0.05),各级CIN病变中Th2类细胞数量变化的差异具有显著性(P<0.05)；转录因子Foxp3阳性的Treg细胞数量增多,但在宫颈炎症、CINⅠ级及CINⅡ级病变中Treg细胞数量变化差异不显著(P>0.05),在CINⅢ级病变中,Treg细胞的数量较其他组显著增多(P<0.05)。
2.应用CCK-8法测定单个核细胞(PBMC)的生长情况发现细胞在前48h处于生长停滞状态,根据细胞生长曲线,以下实验的检测宜在72h-120h内进行。
3.不同浓度SiHa细胞培养上清液作用于CD8+CTL细胞,与空白血清对照组比较,75%培养上清组有统计学差异(P<0.05)；而作用于Treg细胞时,50%培养上清组和75%培养上清组与对照组比较,有统计学差异(P<0.05),故选择75%Siha上清液作为下面实验的干预浓度。
4.免疫磁珠法分离人外周血CD8+T及CD4+CD25+T细胞,经流式细胞术检测CD8+纯度为87.37±0.93%,CD4+CD 25+T细胞纯度为89.12±2.17%。
5.利用CFSE标记CTL,与Treg共培养4天后,CFSE呈单峰,未见明显增殖,而CTL单独培养4天后,可见CFSE呈双峰,即开始出现了细胞增殖,表明Treg对CTL增殖有明显抑制作用。
6.4μg/ml.6μg/m 1.8μg/ml的β-榄香烯均可促进CTL增殖,选择较高的药物浓度8μg/ml作为后续实验的药物干预浓度。1μl/ml.1.5μl/m 1.2μ1/m l的清毒栓醇提水沉液均可促进CTL增殖,选择较高的药物浓度2μl/ml做为后续实验的药物干预浓度。
7.经Western-Blot检测并测定电泳条带灰度值,CTL与Treg共培养组CTLA4、PD1的蛋白表达量明显增加,β-榄香烯及清毒栓干预后CTLA4、PD1的蛋白表达量显著降低,且清毒栓组蛋白表达量降低的更加明显。说明β-榄香烯、清毒栓都可以抑制Treg对CTL中CTLA4.PDl蛋白的上调作用,且清毒栓的作用更显著。
8.清毒栓与安达芬都能有效的降低HC-ⅡHPVR2u/co比值即HPVDNA病毒负荷量,治疗前后自身对照结果有统计学意义(P<0.05),两组比较无显著性差异,与随诊观察组比较有统计学差异(P<0.05)；同时发现两种药物对临床症状、体征的改善作用明显,自身前后对照统计学差异极显著(P<0.01),与随诊观察组比较统计学差异也极显著(P<0.01)。
结论
1.宫颈病变局部免疫微环境中的Th1、Th2类细胞及Treg细胞都参与了宫颈上皮内瘤变的免疫反应,Treg细胞可能通过免疫抑制作用参与病变进展。
2.清毒栓可以降低CTL中CTLA4、PD1蛋白的表达,可能是通过抑制Treg细胞的功能来降低CTLA4、PD1蛋白的表达,从而改变局部免疫微环境而达到抑制肿瘤的作用
3.清毒栓能有效降低宫颈高危型人乳头瘤病毒(HR-HPV)感染的病毒负荷。并能有效改善临床症状、体征。
Object:
1. This research from the view of local lesion immune microenvironment, through researching the immunohistochemical expression of immune microenvironment related transcription factor T-bet, GATA3, Foxp3 in cervical intraepithelial neoplasia tissues, from the cellular level explored the relationship between cervical intraepithelial neoplasia progression and the number of Thl,Th2 and Treg in local lesion immune microenvironment.
2. SiHa cervical cancer cells in the supernatant, CTL, Treg cell co-culture system as an object of study, observation of Treg, Qingdu tied to CTLA-4, PD-1 protein expression to explore the Treg cells in the tumor immune escape mechanism of traditional Chinese medicine suppository on disinfection effect local immune microenvironment.
3. By detecting Qingdu Suppository, AnDafen and followed up for observation of the three groups observed after treatment viral load after 3 months and changes in clinical symptom score, judge drug suppository medicine clear clinical efficacy.
Method:
Empirical study:
1. Select by HE staining, the pathological diagnosis of cervical inflammation and cervical intraepithelial neoplasia of the cervix 128 patients, divided into cervical inflammation, CINⅠgrade, CINⅡgrade and CINⅢgrade 4, in which cervical inflammation, CINⅡgrade lesions 32 Cases, CINⅠgrade of 34 cases and CINⅢgrade lesions of 30 cases.
2. CCK-8 determination of the growth curve of PBMC.
3. SiHa cells with different concentrations of supernatant role in CTL cells and Treg cells, flow cytometry CD8, Treg cell percentage changes.
4. Isolation of human peripheral blood CD8+T cells, Treg cells, flow cytometry cell sorting the purity.
5. CFSE labeling technique using cell value to understand the Treg cells to inhibit the function of CTL cells.
6.4μg/ml,6μg/ml,8μg/ml ofβ-elemene could promote the proliferation of CTL, select a higher concentration of the drug as a follow-up experiments 8p.g/ml concentration of drug intervention. 1μl/ml,1.5μl/ml,2μl/ml the disinfection of water sink plug ethanol solution could promote the proliferation of CTL, select a higher drug concentration 2μl/ml follow-up experiments as the concentration of drug intervention
7. Application of Western-Blot test and compare the CTL normal culture (control group), CTL 50% SiHa supernatants group (cancer supernatant group), CTL+Treg 50% SiHa supernatants group (training group), CTL+ Treg 50% SiHa supernatants+8μg/mlβ-elemene intervention group (β-elemene group), CTL+ Treg 50% SiHa supernatants+2μl/ml ethanol Qingdu suppository water precipitating solution group (Qingdu Suppository Group) five groups CTLA4, PD1 protein expression.
Clinical research:
1. The investigated group comprised 90 patients suffering from cervical HR-HPV infection, which all visited the DongFang Hospital of Beijing University of Chinese Medical, since Aug.2009 to Jan.2011. Randomly divided into treatment group Qingdu Suppository, AnDafen control group, followed up the observation group were treated three groups observed for 3 months. HCⅡdetected by cervical HPVDNA content (viral load) changes, to determine high-risk Qingdu suppository in the treatment of cervical HPV infection in clinical efficacy, but statistical analysis of the clinical symptom score.
Results:
1. With the progression of cervical intraepithelial neoplasia,the number of transcription factors T-bet positive Thl cells were significantly increased (P< 0.05).The number of transcription factors GATA3 positive Th2 cells were decreased, including Th2 celluar number change between cervical inflammation and CIN I was not significant P>0.05),the number changes among every grade of cervical intraepithelial neoplasia were significant (P<0.05).The number of transcription factors Foxp3 positive Treg cells were increased including Treg celluar number changes among cervical inflammation, CINⅠand CINⅡwere not significant (P>0.05),the number of Treg in CINIII was increased significantly (P<0.05)
2. Application of CCK-8 determination of mononuclear cells (PBMC) found that the growth of cell growth and stagnation in the previous 48h, according to cell growth curve, the following experiment testing should be carried out in the 72h-120h.
3. Supernatant of SiHa cells with different concentrations of the role of the CD8+CTL cells, compared with blank control group, serum,75% of the culture supernatant were significantly different (P<0.05); while the effect on Treg cells, 50% of the culture supernatant of group And 75% of the culture supernatant compared with the control group, there are significant differences (P<0.05),75% SiHa supernatant was chosen as the experimental intervention in the following concentrations.
4. Isolation of human peripheral blood CD8+T and CD4+CD25+T cells by flow cytometry CD8+ purity was 87.37±0.93%, CD4+CD25+T cell purity was 89.12±2.17%.
5. CFSE labeled by CTL,4 days after co-culture with Treg, CFSE showed a single peak, no significant proliferation, and CTL 4 days cultured alone, showing a bimodal CFSE, which began to appear in cell proliferation, suggesting that Treg proliferation of CTL inhibit.
6.4μg/ml,6μg/ml,8μg/ml ofβ-elemene could promote the proliferation of CTL, select a higher concentration of the drug as a follow-up experiments 8μg/ml concentration of drug intervention.1μl/ml,1.5μl/ml,2μl/ml the disinfection of water sink plug ethanol solution could promote the proliferation of CTL, select a higher drug concentration 2μl/ml follow-up experiments as the concentration of drug intervention.
7. Application of Western-Blot test and compare the CTL normal culture (control group), CTL 50% SiHa supernatants group (cancer supernatant group), CTL + Treg 50% SiHa supernatants group (training group), CTL + Treg 50% SiHa supernatants +8μg/mlβ-elemene intervention group (β-elemene group), CTL + Treg 50% SiHa supernatants+2μl/ml ethanol Qingdu suppository water precipitating solution group (clear Drug suppository group) five groups CTLA4, PD1 protein expression.
8. Qingdu suppository and AnDafen can effectively reduce HC-ⅡHPVRlu co ratios that HPVDNA viral load, self-control results before and after treatment was statistically significant (P<0.05), showed no significant difference, and with the clinic observed group differ (P<0.05); also found that the two drugs on clinical symptoms and signs improved significantly effect (P<0.01), and followed up for observation group was significantly different (P<0.01).
Conclusion:
1. The local immune microenvironment in cervical lesions in the Th1, Th2 type cells and Treg cells are involved in cervical intraepithelial neoplasia of the immune response, Treg cells may progress through the immunosuppressive effects in disease
2. Qingdu suppository can reduce the CTL in CTLA4, PD1 protein expression probably by inhibiting the function of Treg cells to reduce the CTLA4, PD1 protein expression, thus changing the local immune microenvironment to inhibit tumor effect.
3. Qingdu suppository can reduce cervical high-risk human papillomavirus (HR-HPV) infection in viral load, also can effectively improve the clinical symptoms and signs.
1.通过检测宫颈上皮内瘤变组织局部免疫微环境相关转录因子T-bet、GATA3、Foxp3的免疫组化表达,从细胞水平探讨宫颈上皮内瘤变病程进展与病变局部免疫微环境中Th1、Th2、Treg细胞数量变化的关系
2.以SiHa宫颈癌细胞上清液、CTL、Treg淋巴细胞共培养体系作为研究对象,观察Treg、清毒栓对CTLA-4、PD-1的蛋白表达的影响,探索Treg细胞在肿瘤免疫逃逸中的机制,探讨中药清毒栓对局部免疫微环境的作用。
3.通过检测清毒栓、安达芬及随诊观察三组经治疗观察3个月后病毒负荷及临床症状积分的变化,判断中药清毒栓的临床疗效。
方法
实验研究：
1.选择经HE染色,病理明确诊断为宫颈炎症及宫颈上皮内瘤变的宫颈组织128例,分为宫颈炎症、CINⅠ级、CINⅡ级及CINⅢ级4组,其中宫颈炎症、CINⅡ级病变组织32例,CINⅠ级34例及CINⅢ级病变组织30例。用免疫组化法检测各组组织中免疫微环境相关转录因子T-bet、GATA3、Foxp3阳性细胞的浸润数量,分析以上三种免疫细胞数量变化与病变进展的关系。
2.CCK-8法测定PBMC生长曲线。
3.用不同浓度SiHa细胞培养上清液作用于CTL细胞及Treg细胞,流式细胞术检测CD8、Treg细胞比例变化。
4.免疫磁珠法分离人外周血CD8+T细胞、Treg细胞,流式细胞术检测分选后细胞的纯度。
5.用CFSE标记法检测淋巴细胞增值,了解Treg细胞对CTL细胞的抑制功能。
6.CCK8法测定各浓度β-榄香烯、清毒栓对CTL细胞增殖的影响。
7.应用Western-Blot检测并比较CTL正常培养组(对照组)、CTL+50%SiHa上清培养组(癌上清组)、CTL+Treg+50%SiHa上清培养组(共培养组)CTL+Treg+50%SiHa上清+8μg/mlβ-榄香烯干预组(β-榄香烯组)、CTL+Treg+50％SiHa上清+2μl/ml清毒栓醇提水沉液组(清毒栓组)五组中CTLA4、PD1的蛋白表达情况。
临床研究
选取北京中医药大学东方医院妇科门诊2009年8月～2011年1月就诊的宫颈HR-HPV感染的患者共90例。随机分成清毒栓治疗组、安达芬对照组、随诊观察组三组进行治疗观察3个月。用HCⅡ检测子宫颈HPVDNA含量(病毒负荷)的变化,判断清毒栓治疗高危型宫颈HPV感染的临床疗效,同时进行临床症状积分统计分析。
结果
1.随着宫颈上皮内瘤变病程的进展,转录因子T-be t阳性的Th1类细胞数量增多,各级病变中Thl类细胞数量变化的差异具有显著性(P<0.05)；转录因子GATA 3阳性的Th2类细胞数量减少,其中宫颈炎症与CINⅠ级病变中细胞数量变化差异不显著(P>0.05),各级CIN病变中Th2类细胞数量变化的差异具有显著性(P<0.05)；转录因子Foxp3阳性的Treg细胞数量增多,但在宫颈炎症、CINⅠ级及CINⅡ级病变中Treg细胞数量变化差异不显著(P>0.05),在CINⅢ级病变中,Treg细胞的数量较其他组显著增多(P<0.05)。
2.应用CCK-8法测定单个核细胞(PBMC)的生长情况发现细胞在前48h处于生长停滞状态,根据细胞生长曲线,以下实验的检测宜在72h-120h内进行。
3.不同浓度SiHa细胞培养上清液作用于CD8+CTL细胞,与空白血清对照组比较,75%培养上清组有统计学差异(P<0.05)；而作用于Treg细胞时,50%培养上清组和75%培养上清组与对照组比较,有统计学差异(P<0.05),故选择75%Siha上清液作为下面实验的干预浓度。
4.免疫磁珠法分离人外周血CD8+T及CD4+CD25+T细胞,经流式细胞术检测CD8+纯度为87.37±0.93%,CD4+CD 25+T细胞纯度为89.12±2.17%。
5.利用CFSE标记CTL,与Treg共培养4天后,CFSE呈单峰,未见明显增殖,而CTL单独培养4天后,可见CFSE呈双峰,即开始出现了细胞增殖,表明Treg对CTL增殖有明显抑制作用。
6.4μg/ml.6μg/m 1.8μg/ml的β-榄香烯均可促进CTL增殖,选择较高的药物浓度8μg/ml作为后续实验的药物干预浓度。1μl/ml.1.5μl/m 1.2μ1/m l的清毒栓醇提水沉液均可促进CTL增殖,选择较高的药物浓度2μl/ml做为后续实验的药物干预浓度。
7.经Western-Blot检测并测定电泳条带灰度值,CTL与Treg共培养组CTLA4、PD1的蛋白表达量明显增加,β-榄香烯及清毒栓干预后CTLA4、PD1的蛋白表达量显著降低,且清毒栓组蛋白表达量降低的更加明显。说明β-榄香烯、清毒栓都可以抑制Treg对CTL中CTLA4.PDl蛋白的上调作用,且清毒栓的作用更显著。
8.清毒栓与安达芬都能有效的降低HC-ⅡHPVR2u/co比值即HPVDNA病毒负荷量,治疗前后自身对照结果有统计学意义(P<0.05),两组比较无显著性差异,与随诊观察组比较有统计学差异(P<0.05)；同时发现两种药物对临床症状、体征的改善作用明显,自身前后对照统计学差异极显著(P<0.01),与随诊观察组比较统计学差异也极显著(P<0.01)。
结论
1.宫颈病变局部免疫微环境中的Th1、Th2类细胞及Treg细胞都参与了宫颈上皮内瘤变的免疫反应,Treg细胞可能通过免疫抑制作用参与病变进展。
2.清毒栓可以降低CTL中CTLA4、PD1蛋白的表达,可能是通过抑制Treg细胞的功能来降低CTLA4、PD1蛋白的表达,从而改变局部免疫微环境而达到抑制肿瘤的作用
3.清毒栓能有效降低宫颈高危型人乳头瘤病毒(HR-HPV)感染的病毒负荷。并能有效改善临床症状、体征。
Object:
1. This research from the view of local lesion immune microenvironment, through researching the immunohistochemical expression of immune microenvironment related transcription factor T-bet, GATA3, Foxp3 in cervical intraepithelial neoplasia tissues, from the cellular level explored the relationship between cervical intraepithelial neoplasia progression and the number of Thl,Th2 and Treg in local lesion immune microenvironment.
2. SiHa cervical cancer cells in the supernatant, CTL, Treg cell co-culture system as an object of study, observation of Treg, Qingdu tied to CTLA-4, PD-1 protein expression to explore the Treg cells in the tumor immune escape mechanism of traditional Chinese medicine suppository on disinfection effect local immune microenvironment.
3. By detecting Qingdu Suppository, AnDafen and followed up for observation of the three groups observed after treatment viral load after 3 months and changes in clinical symptom score, judge drug suppository medicine clear clinical efficacy.
Method:
Empirical study:
1. Select by HE staining, the pathological diagnosis of cervical inflammation and cervical intraepithelial neoplasia of the cervix 128 patients, divided into cervical inflammation, CINⅠgrade, CINⅡgrade and CINⅢgrade 4, in which cervical inflammation, CINⅡgrade lesions 32 Cases, CINⅠgrade of 34 cases and CINⅢgrade lesions of 30 cases.
2. CCK-8 determination of the growth curve of PBMC.
3. SiHa cells with different concentrations of supernatant role in CTL cells and Treg cells, flow cytometry CD8, Treg cell percentage changes.
4. Isolation of human peripheral blood CD8+T cells, Treg cells, flow cytometry cell sorting the purity.
5. CFSE labeling technique using cell value to understand the Treg cells to inhibit the function of CTL cells.
6.4μg/ml,6μg/ml,8μg/ml ofβ-elemene could promote the proliferation of CTL, select a higher concentration of the drug as a follow-up experiments 8p.g/ml concentration of drug intervention. 1μl/ml,1.5μl/ml,2μl/ml the disinfection of water sink plug ethanol solution could promote the proliferation of CTL, select a higher drug concentration 2μl/ml follow-up experiments as the concentration of drug intervention
7. Application of Western-Blot test and compare the CTL normal culture (control group), CTL 50% SiHa supernatants group (cancer supernatant group), CTL+Treg 50% SiHa supernatants group (training group), CTL+ Treg 50% SiHa supernatants+8μg/mlβ-elemene intervention group (β-elemene group), CTL+ Treg 50% SiHa supernatants+2μl/ml ethanol Qingdu suppository water precipitating solution group (Qingdu Suppository Group) five groups CTLA4, PD1 protein expression.
Clinical research:
1. The investigated group comprised 90 patients suffering from cervical HR-HPV infection, which all visited the DongFang Hospital of Beijing University of Chinese Medical, since Aug.2009 to Jan.2011. Randomly divided into treatment group Qingdu Suppository, AnDafen control group, followed up the observation group were treated three groups observed for 3 months. HCⅡdetected by cervical HPVDNA content (viral load) changes, to determine high-risk Qingdu suppository in the treatment of cervical HPV infection in clinical efficacy, but statistical analysis of the clinical symptom score.
Results:
1. With the progression of cervical intraepithelial neoplasia,the number of transcription factors T-bet positive Thl cells were significantly increased (P< 0.05).The number of transcription factors GATA3 positive Th2 cells were decreased, including Th2 celluar number change between cervical inflammation and CIN I was not significant P>0.05),the number changes among every grade of cervical intraepithelial neoplasia were significant (P<0.05).The number of transcription factors Foxp3 positive Treg cells were increased including Treg celluar number changes among cervical inflammation, CINⅠand CINⅡwere not significant (P>0.05),the number of Treg in CINIII was increased significantly (P<0.05)
2. Application of CCK-8 determination of mononuclear cells (PBMC) found that the growth of cell growth and stagnation in the previous 48h, according to cell growth curve, the following experiment testing should be carried out in the 72h-120h.
3. Supernatant of SiHa cells with different concentrations of the role of the CD8+CTL cells, compared with blank control group, serum,75% of the culture supernatant were significantly different (P<0.05); while the effect on Treg cells, 50% of the culture supernatant of group And 75% of the culture supernatant compared with the control group, there are significant differences (P<0.05),75% SiHa supernatant was chosen as the experimental intervention in the following concentrations.
4. Isolation of human peripheral blood CD8+T and CD4+CD25+T cells by flow cytometry CD8+ purity was 87.37±0.93%, CD4+CD25+T cell purity was 89.12±2.17%.
5. CFSE labeled by CTL,4 days after co-culture with Treg, CFSE showed a single peak, no significant proliferation, and CTL 4 days cultured alone, showing a bimodal CFSE, which began to appear in cell proliferation, suggesting that Treg proliferation of CTL inhibit.
6.4μg/ml,6μg/ml,8μg/ml ofβ-elemene could promote the proliferation of CTL, select a higher concentration of the drug as a follow-up experiments 8μg/ml concentration of drug intervention.1μl/ml,1.5μl/ml,2μl/ml the disinfection of water sink plug ethanol solution could promote the proliferation of CTL, select a higher drug concentration 2μl/ml follow-up experiments as the concentration of drug intervention.
7. Application of Western-Blot test and compare the CTL normal culture (control group), CTL 50% SiHa supernatants group (cancer supernatant group), CTL + Treg 50% SiHa supernatants group (training group), CTL + Treg 50% SiHa supernatants +8μg/mlβ-elemene intervention group (β-elemene group), CTL + Treg 50% SiHa supernatants+2μl/ml ethanol Qingdu suppository water precipitating solution group (clear Drug suppository group) five groups CTLA4, PD1 protein expression.
8. Qingdu suppository and AnDafen can effectively reduce HC-ⅡHPVRlu co ratios that HPVDNA viral load, self-control results before and after treatment was statistically significant (P<0.05), showed no significant difference, and with the clinic observed group differ (P<0.05); also found that the two drugs on clinical symptoms and signs improved significantly effect (P<0.01), and followed up for observation group was significantly different (P<0.01).
Conclusion:
1. The local immune microenvironment in cervical lesions in the Th1, Th2 type cells and Treg cells are involved in cervical intraepithelial neoplasia of the immune response, Treg cells may progress through the immunosuppressive effects in disease
2. Qingdu suppository can reduce the CTL in CTLA4, PD1 protein expression probably by inhibiting the function of Treg cells to reduce the CTLA4, PD1 protein expression, thus changing the local immune microenvironment to inhibit tumor effect.
3. Qingdu suppository can reduce cervical high-risk human papillomavirus (HR-HPV) infection in viral load, also can effectively improve the clinical symptoms and signs.
引文
1 Lombard I,Vincent-Salomon A,Validier,et al Human papillomvirus genotype as a majoy determinant of the course of cervical cancer[J]. Journal of Clinical Oncology,1998,16(8):2613-2619.
2 Franco EL,Duarate-franco E,et al. Cervical cancer:epidemiology, prevention and the role of human papillomavirus infection [J]. CMAJ,2001,164(7):1017-1025.
3 Markowitz LE,Dunne EF, Saraiya M,et al.Quadrivalent human Papillomavirus vaccine:recommendations of the Advisory Committee on Immunization Practices(ACIP) [J]. MMWR Recommendations and Reports,2007,56:1-24.
4 WangQ, GriffinN, SouthernS,et al.Functional analysis of the human Papillomavirus type 16 E1-E4 protein provides a mechanism for in vivo and in vitro keratin filament reorganization[J] J Virol,2004,78(2):821-33.
5 Villiers EM,Fauquet C,Broker TR,et al.Classification of papillomaviruses[J]. Virology,2004,324:17-27.
6 Gillison ML,Shah KV.Human Papillomavirus Associated Head and Neck Squamous Cell Carcinoma:Mounting Evidence for an Etiologic Role for Human Papillomavirus in a Subset of Head and Neck Cancers [J].Curr Opin Oncol,2001,13:183-188.
7 zur Hausen H.Papillomaviruses Causing Cancer:Evasion from Host Cell Control in Early Events in Carcinogenesis[J].J Natl Cancer Inst,2000,92:690-698.
8 Akiko Kobayashi, Ruth M. Greenblatt,et al. Functional Attributes of Mucosal Immunity in Cervical Intraepithelial Neoplasia and Effects of HIV Infection[J].Cancer Research,2004,64:6766-6774.
9 Fakhry C,D'Souza G,Sugar E,et al.Relationship between prevalent oral and cervical human papillomavirus infections in human immunodeficiency virus-positiveand-negativewomen[J].J Clin Microbiol,2006,44:4479-4485.
10 De Sanjose S, Palefsky J.Cervical and anal HPV infections in HIV positive women and men[J].Virus Res,2002,89:201-211.
11 Konya J,Dillner J.Immunity to oncogenic human papillomaviruses [J].Cancer Res,2001,82:205-238.
12 Huang T G, YeungW S,et al.pRb expressing adenovirus Ad5 Rb attenuates the p53 induced apoptosis in cervical cancer cell lines[J].Eur J Cancer, 2001,37(18):2475-2483.
13 Palefsky J.Cervical and anal HPV infections in HIV positive women and men [J].Virus Res,2002,89:201-211.
14 Kawaida H, Kono K, Takahashi A et al. Distribution of CD4+CD25high regulatory T cells in tumor-draining lymphnodes in patients with gastric cancer [J].J Surgical Research,2005,124(1):151-157.
15邹雄,张利宁主编.分子免疫学与临床.济南：山东科学技术出版社,2003年.
16 Viscidi RP,Schiffman M,Hildesheim A,et al.Seroreactivity to human papillomavirus(HPV) types 16,18 or 31 and risk of subsequent HPV infection:results from a population based study in Costa Rica[J].Cancer Epidemiol Biomarkers Prev,2004,13:324-327.
17 Sheu BC,Chiou SH,Chang WC,et al.Integration of high-risk human papillomavirus DNA correlates with HLA genotype aberration and reduced HLA class I molecule expression in human cervical carcinoma[J].Clin Immunal,2005,115(3):295-301.
18 Georgopoulos NT,Proffitt JL,Blair GE.Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain,TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b,16 and 18 E7 oncoproteins [J].Oncogene,2000,19:4930-4935.
19 Vambutas A,DeVoti J,Pinn W,et al. Interaction of human papillomavirus type 11 E7 protein with Tap21 results in the reduction of ATP-dependent peptide transport [J].Clin Immunol,2001,101:94-99.
20 Knowles H, Leek R, HarrisAL. Macrophage infiltration and angiogenesis in human malignancy[J]. Novartis Found Syrup,2004,256:189-200.
21 Lewis CE, Pollard JW. Distinctrole of macrophages in different tumormicroenvironments[J]. Cancer Res,2006,66(2):605-612.
22 Chen JJ, Lin YC, Yao PL,et al. Tumor-associated macrophages:the double-edged sword in cancer progression[J]. J Clin Oncol,2005,23(5):953-964.
23 Viscidi RPc Schiffman M, Hildesheim A, et al. Seroreactivity to human papinomavirus(HPV)types 16,18 or 31and risk of subsequent HPV infection: results from population based study in costa Rica[J]. cancer Epidemiol Biomarkers Prev,2004,13:324-327.
24 Hammes LS, Tekmal RR,et al.Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression-clinicopathological correlation[J]. Gynecol Oncol.2007,105(1):157-165.
25 Sheu BC, Chiou SH, Chang WC, et al。Integration of high risk human papillomavirus DNA correlates with HLA genotype aberration and reduced HLA class molecule expression in human cervical carcinoma[J]. clin Immunal,2005,115(3): 295-301.
26张圣林,邱法波等.Th1/Th2偏移与恶性肿瘤关系的研究进展[J].细胞与分子免疫学杂志,2005,21：113-114.
27徐林霞,武延隽.HPV感染者Th1/Th2细胞漂移情况研究[J].长治医学院学报,2002,16(1)：728.
28 Stites DP,Moscicki AB.Thl cytokine patterns in cervical human papillomavirus infection[J].Clin Diagn Lab Immunol,1999,6(5):751-755.
29 Saleh W,Giannini SL Jacobs N,et al.Correlation of T elper secretory differentiation and types of antigen-prsenting cells in squamous intraepithelial lesions of the uterine cervix[J].Pathology,1998,184(3):283-290.
30 Warrino DE,Olson WC,Knapp WT,et al.Disease-stage variance infunctional CD4+T cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus 16 E7 epitopes[J].Clin Cancer Res,2004,10 (10):3301-3308.
31 Pardo Govea T,Callejas D,et al.Gamma interferon(IFN-gamma),tumor necrosis factor alpha(TNF-alpha) and interleukins 2,4 and 6(IL-2,IL-4,IL-6) in cervical uterine cells of intraepithelial neoplasia:a preliminary report[J].Invest Clin,2005,46(1):5-13.
32张春霞,任少敏T-bet/GATA3与疾病[J].基础医学与临床,2008,28(3)：286-288.
33 Chabaud M, Lubberts E, Joosten L. et al. IL-17 derived from juxtaarticular one and synovim contributes to jointdegradation in rheumatoid arthritis[J]. ArthrotRes, 2001,3(3):169-177.
34 Valdespino V,Gorodezky C,et al.HPV-16 specific cytotoxic T lymphocyte responses are detected in all HPV-16 positive cervical cancer patients[J].gynecol oncol,2005,96:92-102.
35 Nakagawa M.Stites DP,Palefsky JM,et al. CD4-positive and CD8-positive cytotoxic T lymphocytes contribute to human papillomavirus type 16 E6 and E7 responses[J].Clin Diagn Lab Immunol,1999,6(4):494-498.
36 Gao Q,Qiu SJ,et al.Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection[J].J Clin Oncol,2007 Jun 20;25(18):2506-2508.
37 Benda B,Ljunggren HG,Peach R,et al. Co-stimulatory molecules in Islet Xeno transplantation:CTLA-4 Ig treatment in CD40 ligand-deficient mice[J].Cell Transplant,2002,11(7):7152.
38 Parekh VV, Lalani S,et al. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells[J]. J Immunol,2009,182(5):2816-2826.
39 Nakamoto N,Cho H,et al. Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 Blockade[J].PLoS Pathog, 2009,5(2):e1000313.
40 Sakaguchi S,Sakaguchi N,et al.Immunologic tolerence maintained by CD25+CD4+ regulatory T cells:their commen role in controlling autoimmunity,tumor immunity,and transplantation tolerance [J].Immunol Rev,2001,182:18-32.
41 Wang HY,Lee DA,et al.Tumor specific human CD4+ regulatory T cellsand their ligands:implications for immunotherapy [J]. Immunity,2004,20:107-118.
42 Wolf D,Wolf AM,et al.The expression of regulatory T cell-specific forkhead box transcription factor Foxp3 is associated with poor prognosis in ovarian cancer[J].Clin Cancer Res,2005,11:8326-8331.
43 Liyanage UK, Moore TT,et al. Prevalence of regulatory T cells is increased in peripheral blood and tumormicroenvironment of patients with pancreas or breast adenocarcinoma[J].J Immunol,2002,169:2756-2761.
44 Woo EY, Chu CS,et al. Regulatory CD4+ CD25+ T cells intumors from patients with early-stage non-small cell lung cancer and late-state ovarian cancer[J].Cancer Res,2001,61:4766-4772.
45 J.Visser,H.W.Nijman,et al.Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia[J]. Clinical and Experimental Immunology,2007,150:199-209.
46 Takafumi Nakamura,Tomoko Shima,et al,Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer[J].Cancer science 2007,98:847-881.
47 Curiel TJ,Coukos G,et al.Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J].Nat Med, 2004,10:942-949.
48 Dannull J,Su Z,et al.Enhancement of vaccine-mediated antitumor immunity in cancer pations after deleption of regulatory T cells[J].J Clin Invest, 2005,115:3623-3363.
49 Fontenot JD, GavinMA, Rudensky A Y. Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells[J].Nat Immunol,2003,4:330-336.
50 Khattri R, Cox T, Yasayko S,et al.An essential role for Scurfinin CD4+CD25+T regulatory cells[J].Nat Immunol,2003,4:337-342.
51 Yagi H,Nomura T,Nakamura K,et al.Crucial role of FOXP3 in the development and function of human CD25+CD4+regulatory T cells [J]. Int Immunol,2004,16:1643-1656.
52 Tartour E, Gey A, Sastre-Garau X, et al. Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas [J]. Nat cancer Institute,1998,90(4):287-294.
53 Woodworth CD, Lichti U, Simpson S, et al. Leukoregulinand gamma interferon inhibit human papmomavirus type 16gene transcption in human paplomavirus immortalized human cervical cell [J]. cancer Res,1992,52:456-463.
54 Malejczyk J, Malejczyk M, Breitburd F, et al. Progressivegrowth of human papillomavirus type 16 transformed keratinocvtes is associated with an increased release of solubletumour necrosis factor receptor [J]. J cancer,1996,74:234-239.
55 Musch A Rabe C, PaikMD, et al. Altered expression of TGF. beta receptorsin hepatocellular carcinoma effects of a constitutively active TGF-beta type I receptormutant[J]. Digestion,2005,71(2):78-91.
[1]郭宇飞,孙秀琳.中药诱导肿瘤细胞凋亡的研究[J].世界中医药,2008,3(3)：189-190.
[2]金哲,宋爱武,李仁杰.清毒栓治疗宫颈人乳头瘤病毒感染的临床研究[J].中国中西医结合杂志,2002,22(10)：735-737.
[3]李云波,金哲.清毒栓含药血清对宫颈癌SiHa细胞MDM2基因的影响.中国中西医结合杂志[J].2007,27(2)：147-150.
[4]金哲,李云波.清毒栓血清药理对宫颈癌SiHa细胞P53基因调控作用的研究[J].天津中医药,2007,24(1)：47-50.
[5]于妍妍,楼姣英,金哲.中药清毒栓对宫颈癌SiHa细胞凋亡的影响[J].疑难病杂志,2008,7(9)：531-533.
[6]周永芹,韩莉.蜈蚣提取物对宫颈癌Caski细胞增殖的抑制效应[J].中国组织工程研究与临床康复,2007,11(34)：6805-6807.
[7]谭朝阳,何迎春等.茜草提取物对宫颈癌HeLa细胞杀伤动力学研究[J].中医药学刊,2004,22(12)：2213-2214.
[8]李煜,王振飞等.大蓟提取液对4种癌细胞生长抑制作用的研究[J].时珍国医国药,2008,19(2)：265-267.
[9]王振飞,李煜等.地榆水提液对四种癌细胞生长抑制作用的研究.时珍国医国药[J].2008,19(3)：671-672.
[10]吴琳华,郭劲柏等.仙鹤草注射液对人癌细胞生长抑制作用的研究.中国中医药科技[J].2005,12(5)：297-298.
[11]李桂玲,归绥琪等.掌叶半夏提取物的有效部位对体外培养宫颈癌细胞的促凋亡作用[J].中华中医药杂志,2008,23(5)：447-449.
[12]马宁,苑春莉.红景天对宫颈癌Hela细胞增殖的抑制作用[J].江西中医药,2006,37(6)：55-56.
[13]王恩军,靳祎等.刺五加注射液对Hela细胞抑制作用的实验研究[J].河北北方学院学报(医学版),2008,25(2)：19-21.
[14]李尘远,刘玲等.玉竹提取物B对Hela细胞的抑制作用[J].锦州医学院学报,2003,24(5)：1-2.
[15]梁克明,谢艳华等.九节龙皂甙对Hela细胞生长的抑制作用[J].第三军医大学学报,2002,24(6)：15-18.
[16]来丽娜,赵娜等.小檗碱对HeLa细胞凋亡及其凋亡相关蛋白表达的影响[J].中草药,2008,39(2)：244-247.
[17]狄晓鸿,高英敏等.黄连素对人宫颈癌Hela细胞株的体外作用研究[J].中国中医药信息杂志,2008,15(1)：30-31.
[18]林传远,施贻.柴胡解毒汤治疗生殖道HPV感染的临床运用.赣南医学院学报,2007,27(3)：427-428.
[19]黄志欣,吴秀霞,廖莳,许学岚,姚仕萍.中药保妇康拴在HPV感染宫颈病变患者中的应用研究,中国医师杂志,2007,9(8)：1128-1130.
[20]王锦泳.HPV中医药特色疗法与现代高科技相结合研究探讨.中华现代中医学杂,2005,1(2)：106-109.
[21]金哲,楼姣英.清毒栓治疗宫颈人乳头瘤病毒(HPV)亚临床感染地临床研究.中华中西医临床杂志,2006,1(2)：20-22.
[22]王勒渝,李理等.宫颈Ⅰ号栓阻断宫颈癌发生的组织病理学、超微结构及免疫组织化学的研究[J].中国中医药科技,1999,6(5)：293-296.
[23]黄志欣.中药保妇康栓在HPV感染宫颈病变患者中的应用研究[J].中国医师杂志,2007,9(8)：1128-1130.
[24]吴小平,阿军.湿疣的中西医治疗及理疗治疗,中华中西医学志,2005,3(3)：96.
[25]颜向东,颜彤,于志华.中西医结合治愈31例尖锐湿疣中华临床医学研究杂志,2006,12(22)：3085-3086.
[26]孟涛.清毒虎苡汤配合以CO2激光治疗尖锐湿疣700例.皮肤病与性病,2002,(3)：47.
[1]郎景和.迎接子宫颈癌预防的全球挑战与机遇[J].中华妇产科杂志,2002,37：1291.
[2]Akiko Kobayashi,Ruth M. Greenblatt,et al.Functional Attributes of Mucosal Immunity in Cervical Intraepithelial Neoplasia and Effects of HIV Infection[J].Cancer Research,2004,64:6766-6774.
[3]Fakhry C,D'Souza G,Sugar E,et al.Relationship between prevalent oral and cervical human papillomavirus infections in human immunodeficiency virus-positive and-negative women[J].J Clin Microbiol,2006,44:4479-85.
[4]de Sanjose S,Palefsky J.Cervical and anal HPV infections in HIV positive women and men[J].Virus Res,2002,89:201-11.
[5]张春霞,任少敏T-bet/GATA3与疾病[J].基础医学与临床,2008,28(3)：286-288.
[6]Sakaguchi S,Sakaguchi N,et al.Immunologic tolerence maintained by CD25+CD4+ regulatory T cells:their commen role in controlling autoimmunity,tumor immunity,and transplantation tolerance[J].Immunol Rev,2001,182:18-32.
[7]Wang HY,Lee DA,et al.Tumor specific human CD4+ regulatory T cellsand their ligands:implications for immunotherapy[J].Immunity,2004,20:107-118.
[8]Khattri R,Cox T,Yasayko S,et al.An essential role for Scurfinin CD4+CD25+ T regulatory cells[J].Nat Immunol,2003,4:337-342.
[9]Yagi H,Nomura T,Nakamura K,et al.Crucial role of FOXP3 in the development and function of human CD25+ CD4+ regulatory T cells[J].Int Immunol,2004,16:1643-1656.
[10]Pardo Govea T,Callejas D,et al.Gamma interferon(IFN-gamma),tumor necrosis factor alpha (TNF-alpha) and interleukins 2,4 and 6(IL-2,IL-4,IL-6) in cervical uterine cells of intraepithelial neoplasia:a preliminary report[J].Invest Clin,2005,46(1):5-13.
[11]Renske D.M.Steenbergen,Vanessa E.OudeEngberink,et al.Downregulation of GATA-3 Expression during Human Papillomavirus-Mediated Immortalization and Cervical Carcinogenesis[J].American Journal of Pathology,2002,160(6):1945-1951.
1 Mosmann T. Rap id col orimetric assay for cellular growth and sur2 vival:app lication to p roliferation and cytot oxicity assays [J]. JI mmunolMethods,1983, 65(1-2):55-65.
2 Tominaga H, IshiyamaM,Ohset o F, et al. A water2s oluble tetrazoli2um salt useful for col orimetric cell viability assay [J]. Anal Com2mun,1999,36:47-50.
1 Nizar S, Copier J, Meyer B et, T-regulatory cell modulatioll; the future Of cancer immunotherapy? [J]. Br J Cancer,2009; 100(11):1697-1703.
2 Beyer M, Schultze J L. Regulatory T cells:major players in the tumor mi-croenvironment[J]. Curr Pharm Des,2009; 15(16):1879-1892.
3 liyanage U K, Moore T T, JooH G et al. Prevalence Of regulation T cells is increased in peripheral blood and tumor microenvironment of patientswith pancreas orbreast adenocarcinoma[J]. J Immunol,2002; 169(5):2756-2761.
4 Wolf A M, Wolf D, Steurer M et al, Increase Of regulatory T cells in the peripheral blood of cancer patients. [J]. Clin Cancer Res,2003; 9(2):606-612.
5崔永生,李欣,于春雷etal肺癌和乳腺癌患者外周血中CD4+CD25+T细胞及fox3 mRNA的变化特点及临床意义[J].吉林大学学报医学版,2006；32(5)：843-846.
6李欣,崔永生,王炎et al. CD4+CD25+调节性T细胞在Lewis肺癌移植 鼠中的检测及临床意义[J].现代肿瘤医学,2007；15(4)：454-457.
1 S. sakaguchi, N.Sakaguchi, M.Asano,M.Itoh, and M.Toda. Immunologic self-tolerance maintained by aetivated T cells expressing IL-2 receptor alpha-chains (CD25). Break down of a single mechanism of self-tolerance causes various Autoimmune diseases. J Immunol,1995,155:1151-1164.
2 M.G.Roncarolo,S.Gregori,M.Battaglia,R.Bacchetta,K.Fleischhauer,and M.K.Levings. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev,2006,212:28-50.
3 Battaglia, M., Stabilini, A., Draghici, E., et al. (2006) Induction of tolerance in type 1 diabetes via both CD4+CD25+T regulatory cells and T regulatory type 1 cells. Diabetes 6,1571-1580.
4 Crotty S, Kersh EN, Cannons J, et al. SAP is required for generating long-term humoral immunity [J]. Nature,2003,421 (16):282-287.
1 Lyons AB, Parish CR. Determination of lymphocyte division by follow cytometry [J]. Immunol Methods.1994,171(1):131-137.
2李涛,孙振武,李玉晓,等CFSE标记技术及其在细胞研究中的应用进展[J].现代生物学进展.2007.7(2)：316-317.
1 Klenerman P, Hill A. Tcells and viral persistence:lessons from diverse infections. Nat Immunol,2005,6(9):873-879.
2 Parekh VV, Lalani S,et al. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells[J]. J Immunol,2009,182(5):2816-2826.
3 Nakamoto N,Cho H,et al. Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 Blockade[J].PLoS Pathog, 2009,5(2):e1000313.
4 Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature,2006,433(7109):350-354.
5 Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8+T cells leads to reversible immune dysfunction. Nat Med,2006,12(10): 1198-1202.
6 Petrovas C, Casazza JP, Brenchley JM, et al. PD-1 is a regulator of virus-specific CD8+T cell survival inHIV infection. J ExpMed,2006,203(10):2281-2292.
7 Mayer L.Mucosal immunity. Pediatrics,2003,111 (6 Pt3):1595-1600.
8 Das G,Augustine MM,Das J,et al. A important regulatory role for CD4+CD8ααT cells in the intestional epithelial layer in the prevention of inflammatory bowel disease. Proc Natl Acad Sci USA,2003,100 (9):5324-5329.
1 Lombard I,Vincent-Salomon A,Validier,et al Human papillomvirus genotype as a majoy determinant of the course of cervical cancer[J]. Journal of Clinical Oncology,1998,16(8):2613-2619.
2 Franco EL,Duarate-franco E,et al. Cervical cancer:epidemiology, prevention and the role of human papillomavirus infection [J]. CMAJ,2001,164(7):1017-1025.
3 金哲,李云波.消毒栓血清药理对宫颈癌SiHa细胞P53基因调控作用的研究[J].天津中医药,2007,24(1)：47-50.
4 李云渡,金哲.消毒栓含药血清对宫颈癌SiHa细胞MDM2基因的影响[J].中国中西医结合杂志,2007,(27)2：147-150.5楼姣英,金哲,李云波.消毒辁血清药对宫颈癌SiHa细胞凋亡及周期的影响[J].北京中医药.2008,27(7)：563-565.
6金哲,宋爱武,李仁杰.清毒栓治疗宫颈人乳头瘤病毒感染的临床研究.中国中西医结合杂志2002；10(10)：735-737.
7 金哲,楼姣英.清毒栓治疗宫颈人乳头瘤病毒(HPV)亚临床感染地临床研究.中华中西医临床杂志,2006,1(2)：20-22.
8 Stevens MP, Tabrizi SN, Quirm MA, et al. Human papilomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne, Australia[J]. Int J Gynecol Cancer,2006,16(3):1017-1024.
9 Andersson S, Safari H, Mints M, et al. Type distribution, viral load and integration status of high-risk human papillomaviruses in prestages of cervical cancer(CIN). Br J Cancer,2005,92(12):2195-2200.
10 Zhao FH, et al. Associations of high-risk HPV types and viral load with cervical cancer in China. J Clin virol,2006,35:264-269.
11 de Cremoux P, de la Rochefordibre A, Savignoni A, et al. Different outcome of invasive cervical cancer associated with high-risk versus intermediate-risk HPVgenotype. Int J Cancer,2009; 124(4):778-782.
12 M Zerbini, et al. Distribution and viral load of type specific HPVs in different cervical lesion as detected by PCR-EUSA. J. Cain. Path01.2001, 54:377-380.
13 X Castellsague, et al. Chapter 3:Cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives, and tobacco smoking. J Nail Cancer Inst Monoger,2003,31:20-28.
14 Chua KL,Wiklund F,Lenner P,et al.Aprospective study on the risk of cervical intraepithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPVDNA in cervical smears.Int J Cancer,1996,68:54-59.
15 Kaufman RH,Adam E, Icenogle J,et al.Relevance of human papillomavirus screening in management of cervical intraepithelial neoplasia. Am J Obstet Gyneo,1997,176:87-92.
16 A Hildesheim and sS Wang. Host and viral genetics and risk of cervical cancer:a review. Virus Res,2002,89(2):229-240.
17 M Arbyn, et al. Virologic Versus Cytologic Triage of Women With Equivocal PaP Smear:A Meta-analysis of the Accuracy To Detect High-Glade Intraepithelial Neoplasia. J Natl Cancer Inst,2004,96:280-293.
18尚春霞,李红英,尚素霜,张静.奥平-干扰素栓治疗宫颈入乳头瘤病毒亚临床感染的疗效观察.河北医药,2007,29(5)：476-478.
19 Rivera A, Tyring SK. Therapy of cutaneous human papilloma virus infections. Dermatol Ther,2004,17(6):441-448.
2 Franco EL,Duarate-franco E,et al. Cervical cancer:epidemiology, prevention and the role of human papillomavirus infection [J]. CMAJ,2001,164(7):1017-1025.
3 Markowitz LE,Dunne EF, Saraiya M,et al.Quadrivalent human Papillomavirus vaccine:recommendations of the Advisory Committee on Immunization Practices(ACIP) [J]. MMWR Recommendations and Reports,2007,56:1-24.
4 WangQ, GriffinN, SouthernS,et al.Functional analysis of the human Papillomavirus type 16 E1-E4 protein provides a mechanism for in vivo and in vitro keratin filament reorganization[J] J Virol,2004,78(2):821-33.
5 Villiers EM,Fauquet C,Broker TR,et al.Classification of papillomaviruses[J]. Virology,2004,324:17-27.
6 Gillison ML,Shah KV.Human Papillomavirus Associated Head and Neck Squamous Cell Carcinoma:Mounting Evidence for an Etiologic Role for Human Papillomavirus in a Subset of Head and Neck Cancers [J].Curr Opin Oncol,2001,13:183-188.
7 zur Hausen H.Papillomaviruses Causing Cancer:Evasion from Host Cell Control in Early Events in Carcinogenesis[J].J Natl Cancer Inst,2000,92:690-698.
8 Akiko Kobayashi, Ruth M. Greenblatt,et al. Functional Attributes of Mucosal Immunity in Cervical Intraepithelial Neoplasia and Effects of HIV Infection[J].Cancer Research,2004,64:6766-6774.
9 Fakhry C,D'Souza G,Sugar E,et al.Relationship between prevalent oral and cervical human papillomavirus infections in human immunodeficiency virus-positiveand-negativewomen[J].J Clin Microbiol,2006,44:4479-4485.
10 De Sanjose S, Palefsky J.Cervical and anal HPV infections in HIV positive women and men[J].Virus Res,2002,89:201-211.
11 Konya J,Dillner J.Immunity to oncogenic human papillomaviruses [J].Cancer Res,2001,82:205-238.
12 Huang T G, YeungW S,et al.pRb expressing adenovirus Ad5 Rb attenuates the p53 induced apoptosis in cervical cancer cell lines[J].Eur J Cancer, 2001,37(18):2475-2483.
13 Palefsky J.Cervical and anal HPV infections in HIV positive women and men [J].Virus Res,2002,89:201-211.
14 Kawaida H, Kono K, Takahashi A et al. Distribution of CD4+CD25high regulatory T cells in tumor-draining lymphnodes in patients with gastric cancer [J].J Surgical Research,2005,124(1):151-157.
15邹雄,张利宁主编.分子免疫学与临床.济南：山东科学技术出版社,2003年.
16 Viscidi RP,Schiffman M,Hildesheim A,et al.Seroreactivity to human papillomavirus(HPV) types 16,18 or 31 and risk of subsequent HPV infection:results from a population based study in Costa Rica[J].Cancer Epidemiol Biomarkers Prev,2004,13:324-327.
17 Sheu BC,Chiou SH,Chang WC,et al.Integration of high-risk human papillomavirus DNA correlates with HLA genotype aberration and reduced HLA class I molecule expression in human cervical carcinoma[J].Clin Immunal,2005,115(3):295-301.
18 Georgopoulos NT,Proffitt JL,Blair GE.Transcriptional regulation of the major histocompatibility complex (MHC) class I heavy chain,TAP1 and LMP2 genes by the human papillomavirus (HPV) type 6b,16 and 18 E7 oncoproteins [J].Oncogene,2000,19:4930-4935.
19 Vambutas A,DeVoti J,Pinn W,et al. Interaction of human papillomavirus type 11 E7 protein with Tap21 results in the reduction of ATP-dependent peptide transport [J].Clin Immunol,2001,101:94-99.
20 Knowles H, Leek R, HarrisAL. Macrophage infiltration and angiogenesis in human malignancy[J]. Novartis Found Syrup,2004,256:189-200.
21 Lewis CE, Pollard JW. Distinctrole of macrophages in different tumormicroenvironments[J]. Cancer Res,2006,66(2):605-612.
22 Chen JJ, Lin YC, Yao PL,et al. Tumor-associated macrophages:the double-edged sword in cancer progression[J]. J Clin Oncol,2005,23(5):953-964.
23 Viscidi RPc Schiffman M, Hildesheim A, et al. Seroreactivity to human papinomavirus(HPV)types 16,18 or 31and risk of subsequent HPV infection: results from population based study in costa Rica[J]. cancer Epidemiol Biomarkers Prev,2004,13:324-327.
24 Hammes LS, Tekmal RR,et al.Macrophages, inflammation and risk of cervical intraepithelial neoplasia (CIN) progression-clinicopathological correlation[J]. Gynecol Oncol.2007,105(1):157-165.
25 Sheu BC, Chiou SH, Chang WC, et al。Integration of high risk human papillomavirus DNA correlates with HLA genotype aberration and reduced HLA class molecule expression in human cervical carcinoma[J]. clin Immunal,2005,115(3): 295-301.
26张圣林,邱法波等.Th1/Th2偏移与恶性肿瘤关系的研究进展[J].细胞与分子免疫学杂志,2005,21：113-114.
27徐林霞,武延隽.HPV感染者Th1/Th2细胞漂移情况研究[J].长治医学院学报,2002,16(1)：728.
28 Stites DP,Moscicki AB.Thl cytokine patterns in cervical human papillomavirus infection[J].Clin Diagn Lab Immunol,1999,6(5):751-755.
29 Saleh W,Giannini SL Jacobs N,et al.Correlation of T elper secretory differentiation and types of antigen-prsenting cells in squamous intraepithelial lesions of the uterine cervix[J].Pathology,1998,184(3):283-290.
30 Warrino DE,Olson WC,Knapp WT,et al.Disease-stage variance infunctional CD4+T cell responses against novel pan-human leukocyte antigen-D region presented human papillomavirus 16 E7 epitopes[J].Clin Cancer Res,2004,10 (10):3301-3308.
31 Pardo Govea T,Callejas D,et al.Gamma interferon(IFN-gamma),tumor necrosis factor alpha(TNF-alpha) and interleukins 2,4 and 6(IL-2,IL-4,IL-6) in cervical uterine cells of intraepithelial neoplasia:a preliminary report[J].Invest Clin,2005,46(1):5-13.
32张春霞,任少敏T-bet/GATA3与疾病[J].基础医学与临床,2008,28(3)：286-288.
33 Chabaud M, Lubberts E, Joosten L. et al. IL-17 derived from juxtaarticular one and synovim contributes to jointdegradation in rheumatoid arthritis[J]. ArthrotRes, 2001,3(3):169-177.
34 Valdespino V,Gorodezky C,et al.HPV-16 specific cytotoxic T lymphocyte responses are detected in all HPV-16 positive cervical cancer patients[J].gynecol oncol,2005,96:92-102.
35 Nakagawa M.Stites DP,Palefsky JM,et al. CD4-positive and CD8-positive cytotoxic T lymphocytes contribute to human papillomavirus type 16 E6 and E7 responses[J].Clin Diagn Lab Immunol,1999,6(4):494-498.
36 Gao Q,Qiu SJ,et al.Intratumoral balance of regulatory and cytotoxic T cells is associated with prognosis of hepatocellular carcinoma after resection[J].J Clin Oncol,2007 Jun 20;25(18):2506-2508.
37 Benda B,Ljunggren HG,Peach R,et al. Co-stimulatory molecules in Islet Xeno transplantation:CTLA-4 Ig treatment in CD40 ligand-deficient mice[J].Cell Transplant,2002,11(7):7152.
38 Parekh VV, Lalani S,et al. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells[J]. J Immunol,2009,182(5):2816-2826.
39 Nakamoto N,Cho H,et al. Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 Blockade[J].PLoS Pathog, 2009,5(2):e1000313.
40 Sakaguchi S,Sakaguchi N,et al.Immunologic tolerence maintained by CD25+CD4+ regulatory T cells:their commen role in controlling autoimmunity,tumor immunity,and transplantation tolerance [J].Immunol Rev,2001,182:18-32.
41 Wang HY,Lee DA,et al.Tumor specific human CD4+ regulatory T cellsand their ligands:implications for immunotherapy [J]. Immunity,2004,20:107-118.
42 Wolf D,Wolf AM,et al.The expression of regulatory T cell-specific forkhead box transcription factor Foxp3 is associated with poor prognosis in ovarian cancer[J].Clin Cancer Res,2005,11:8326-8331.
43 Liyanage UK, Moore TT,et al. Prevalence of regulatory T cells is increased in peripheral blood and tumormicroenvironment of patients with pancreas or breast adenocarcinoma[J].J Immunol,2002,169:2756-2761.
44 Woo EY, Chu CS,et al. Regulatory CD4+ CD25+ T cells intumors from patients with early-stage non-small cell lung cancer and late-state ovarian cancer[J].Cancer Res,2001,61:4766-4772.
45 J.Visser,H.W.Nijman,et al.Frequencies and role of regulatory T cells in patients with (pre)malignant cervical neoplasia[J]. Clinical and Experimental Immunology,2007,150:199-209.
46 Takafumi Nakamura,Tomoko Shima,et al,Expression of indoleamine 2, 3-dioxygenase and the recruitment of Foxp3-expressing regulatory T cells in the development and progression of uterine cervical cancer[J].Cancer science 2007,98:847-881.
47 Curiel TJ,Coukos G,et al.Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J].Nat Med, 2004,10:942-949.
48 Dannull J,Su Z,et al.Enhancement of vaccine-mediated antitumor immunity in cancer pations after deleption of regulatory T cells[J].J Clin Invest, 2005,115:3623-3363.
49 Fontenot JD, GavinMA, Rudensky A Y. Foxp3 programs the development and function of CD4+ CD25+ regulatory T cells[J].Nat Immunol,2003,4:330-336.
50 Khattri R, Cox T, Yasayko S,et al.An essential role for Scurfinin CD4+CD25+T regulatory cells[J].Nat Immunol,2003,4:337-342.
51 Yagi H,Nomura T,Nakamura K,et al.Crucial role of FOXP3 in the development and function of human CD25+CD4+regulatory T cells [J]. Int Immunol,2004,16:1643-1656.
52 Tartour E, Gey A, Sastre-Garau X, et al. Prognostic value of intratumoral interferon gamma messenger RNA expression in invasive cervical carcinomas [J]. Nat cancer Institute,1998,90(4):287-294.
53 Woodworth CD, Lichti U, Simpson S, et al. Leukoregulinand gamma interferon inhibit human papmomavirus type 16gene transcption in human paplomavirus immortalized human cervical cell [J]. cancer Res,1992,52:456-463.
54 Malejczyk J, Malejczyk M, Breitburd F, et al. Progressivegrowth of human papillomavirus type 16 transformed keratinocvtes is associated with an increased release of solubletumour necrosis factor receptor [J]. J cancer,1996,74:234-239.
55 Musch A Rabe C, PaikMD, et al. Altered expression of TGF. beta receptorsin hepatocellular carcinoma effects of a constitutively active TGF-beta type I receptormutant[J]. Digestion,2005,71(2):78-91.
[1]郭宇飞,孙秀琳.中药诱导肿瘤细胞凋亡的研究[J].世界中医药,2008,3(3)：189-190.
[2]金哲,宋爱武,李仁杰.清毒栓治疗宫颈人乳头瘤病毒感染的临床研究[J].中国中西医结合杂志,2002,22(10)：735-737.
[3]李云波,金哲.清毒栓含药血清对宫颈癌SiHa细胞MDM2基因的影响.中国中西医结合杂志[J].2007,27(2)：147-150.
[4]金哲,李云波.清毒栓血清药理对宫颈癌SiHa细胞P53基因调控作用的研究[J].天津中医药,2007,24(1)：47-50.
[5]于妍妍,楼姣英,金哲.中药清毒栓对宫颈癌SiHa细胞凋亡的影响[J].疑难病杂志,2008,7(9)：531-533.
[6]周永芹,韩莉.蜈蚣提取物对宫颈癌Caski细胞增殖的抑制效应[J].中国组织工程研究与临床康复,2007,11(34)：6805-6807.
[7]谭朝阳,何迎春等.茜草提取物对宫颈癌HeLa细胞杀伤动力学研究[J].中医药学刊,2004,22(12)：2213-2214.
[8]李煜,王振飞等.大蓟提取液对4种癌细胞生长抑制作用的研究[J].时珍国医国药,2008,19(2)：265-267.
[9]王振飞,李煜等.地榆水提液对四种癌细胞生长抑制作用的研究.时珍国医国药[J].2008,19(3)：671-672.
[10]吴琳华,郭劲柏等.仙鹤草注射液对人癌细胞生长抑制作用的研究.中国中医药科技[J].2005,12(5)：297-298.
[11]李桂玲,归绥琪等.掌叶半夏提取物的有效部位对体外培养宫颈癌细胞的促凋亡作用[J].中华中医药杂志,2008,23(5)：447-449.
[12]马宁,苑春莉.红景天对宫颈癌Hela细胞增殖的抑制作用[J].江西中医药,2006,37(6)：55-56.
[13]王恩军,靳祎等.刺五加注射液对Hela细胞抑制作用的实验研究[J].河北北方学院学报(医学版),2008,25(2)：19-21.
[14]李尘远,刘玲等.玉竹提取物B对Hela细胞的抑制作用[J].锦州医学院学报,2003,24(5)：1-2.
[15]梁克明,谢艳华等.九节龙皂甙对Hela细胞生长的抑制作用[J].第三军医大学学报,2002,24(6)：15-18.
[16]来丽娜,赵娜等.小檗碱对HeLa细胞凋亡及其凋亡相关蛋白表达的影响[J].中草药,2008,39(2)：244-247.
[17]狄晓鸿,高英敏等.黄连素对人宫颈癌Hela细胞株的体外作用研究[J].中国中医药信息杂志,2008,15(1)：30-31.
[18]林传远,施贻.柴胡解毒汤治疗生殖道HPV感染的临床运用.赣南医学院学报,2007,27(3)：427-428.
[19]黄志欣,吴秀霞,廖莳,许学岚,姚仕萍.中药保妇康拴在HPV感染宫颈病变患者中的应用研究,中国医师杂志,2007,9(8)：1128-1130.
[20]王锦泳.HPV中医药特色疗法与现代高科技相结合研究探讨.中华现代中医学杂,2005,1(2)：106-109.
[21]金哲,楼姣英.清毒栓治疗宫颈人乳头瘤病毒(HPV)亚临床感染地临床研究.中华中西医临床杂志,2006,1(2)：20-22.
[22]王勒渝,李理等.宫颈Ⅰ号栓阻断宫颈癌发生的组织病理学、超微结构及免疫组织化学的研究[J].中国中医药科技,1999,6(5)：293-296.
[23]黄志欣.中药保妇康栓在HPV感染宫颈病变患者中的应用研究[J].中国医师杂志,2007,9(8)：1128-1130.
[24]吴小平,阿军.湿疣的中西医治疗及理疗治疗,中华中西医学志,2005,3(3)：96.
[25]颜向东,颜彤,于志华.中西医结合治愈31例尖锐湿疣中华临床医学研究杂志,2006,12(22)：3085-3086.
[26]孟涛.清毒虎苡汤配合以CO2激光治疗尖锐湿疣700例.皮肤病与性病,2002,(3)：47.
[1]郎景和.迎接子宫颈癌预防的全球挑战与机遇[J].中华妇产科杂志,2002,37：1291.
[2]Akiko Kobayashi,Ruth M. Greenblatt,et al.Functional Attributes of Mucosal Immunity in Cervical Intraepithelial Neoplasia and Effects of HIV Infection[J].Cancer Research,2004,64:6766-6774.
[3]Fakhry C,D'Souza G,Sugar E,et al.Relationship between prevalent oral and cervical human papillomavirus infections in human immunodeficiency virus-positive and-negative women[J].J Clin Microbiol,2006,44:4479-85.
[4]de Sanjose S,Palefsky J.Cervical and anal HPV infections in HIV positive women and men[J].Virus Res,2002,89:201-11.
[5]张春霞,任少敏T-bet/GATA3与疾病[J].基础医学与临床,2008,28(3)：286-288.
[6]Sakaguchi S,Sakaguchi N,et al.Immunologic tolerence maintained by CD25+CD4+ regulatory T cells:their commen role in controlling autoimmunity,tumor immunity,and transplantation tolerance[J].Immunol Rev,2001,182:18-32.
[7]Wang HY,Lee DA,et al.Tumor specific human CD4+ regulatory T cellsand their ligands:implications for immunotherapy[J].Immunity,2004,20:107-118.
[8]Khattri R,Cox T,Yasayko S,et al.An essential role for Scurfinin CD4+CD25+ T regulatory cells[J].Nat Immunol,2003,4:337-342.
[9]Yagi H,Nomura T,Nakamura K,et al.Crucial role of FOXP3 in the development and function of human CD25+ CD4+ regulatory T cells[J].Int Immunol,2004,16:1643-1656.
[10]Pardo Govea T,Callejas D,et al.Gamma interferon(IFN-gamma),tumor necrosis factor alpha (TNF-alpha) and interleukins 2,4 and 6(IL-2,IL-4,IL-6) in cervical uterine cells of intraepithelial neoplasia:a preliminary report[J].Invest Clin,2005,46(1):5-13.
[11]Renske D.M.Steenbergen,Vanessa E.OudeEngberink,et al.Downregulation of GATA-3 Expression during Human Papillomavirus-Mediated Immortalization and Cervical Carcinogenesis[J].American Journal of Pathology,2002,160(6):1945-1951.
1 Mosmann T. Rap id col orimetric assay for cellular growth and sur2 vival:app lication to p roliferation and cytot oxicity assays [J]. JI mmunolMethods,1983, 65(1-2):55-65.
2 Tominaga H, IshiyamaM,Ohset o F, et al. A water2s oluble tetrazoli2um salt useful for col orimetric cell viability assay [J]. Anal Com2mun,1999,36:47-50.
1 Nizar S, Copier J, Meyer B et, T-regulatory cell modulatioll; the future Of cancer immunotherapy? [J]. Br J Cancer,2009; 100(11):1697-1703.
2 Beyer M, Schultze J L. Regulatory T cells:major players in the tumor mi-croenvironment[J]. Curr Pharm Des,2009; 15(16):1879-1892.
3 liyanage U K, Moore T T, JooH G et al. Prevalence Of regulation T cells is increased in peripheral blood and tumor microenvironment of patientswith pancreas orbreast adenocarcinoma[J]. J Immunol,2002; 169(5):2756-2761.
4 Wolf A M, Wolf D, Steurer M et al, Increase Of regulatory T cells in the peripheral blood of cancer patients. [J]. Clin Cancer Res,2003; 9(2):606-612.
5崔永生,李欣,于春雷etal肺癌和乳腺癌患者外周血中CD4+CD25+T细胞及fox3 mRNA的变化特点及临床意义[J].吉林大学学报医学版,2006；32(5)：843-846.
6李欣,崔永生,王炎et al. CD4+CD25+调节性T细胞在Lewis肺癌移植 鼠中的检测及临床意义[J].现代肿瘤医学,2007；15(4)：454-457.
1 S. sakaguchi, N.Sakaguchi, M.Asano,M.Itoh, and M.Toda. Immunologic self-tolerance maintained by aetivated T cells expressing IL-2 receptor alpha-chains (CD25). Break down of a single mechanism of self-tolerance causes various Autoimmune diseases. J Immunol,1995,155:1151-1164.
2 M.G.Roncarolo,S.Gregori,M.Battaglia,R.Bacchetta,K.Fleischhauer,and M.K.Levings. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol Rev,2006,212:28-50.
3 Battaglia, M., Stabilini, A., Draghici, E., et al. (2006) Induction of tolerance in type 1 diabetes via both CD4+CD25+T regulatory cells and T regulatory type 1 cells. Diabetes 6,1571-1580.
4 Crotty S, Kersh EN, Cannons J, et al. SAP is required for generating long-term humoral immunity [J]. Nature,2003,421 (16):282-287.
1 Lyons AB, Parish CR. Determination of lymphocyte division by follow cytometry [J]. Immunol Methods.1994,171(1):131-137.
2李涛,孙振武,李玉晓,等CFSE标记技术及其在细胞研究中的应用进展[J].现代生物学进展.2007.7(2)：316-317.
1 Klenerman P, Hill A. Tcells and viral persistence:lessons from diverse infections. Nat Immunol,2005,6(9):873-879.
2 Parekh VV, Lalani S,et al. PD-1/PD-L blockade prevents anergy induction and enhances the anti-tumor activities of glycolipid-activated invariant NKT cells[J]. J Immunol,2009,182(5):2816-2826.
3 Nakamoto N,Cho H,et al. Synergistic Reversal of Intrahepatic HCV-Specific CD8 T Cell Exhaustion by Combined PD-1/CTLA-4 Blockade[J].PLoS Pathog, 2009,5(2):e1000313.
4 Day CL, Kaufmann DE, Kiepiela P, et al. PD-1 expression on HIV-specific T cells is associated with T-cell exhaustion and disease progression. Nature,2006,433(7109):350-354.
5 Trautmann L, Janbazian L, Chomont N, et al. Upregulation of PD-1 expression on HIV-specific CD8+T cells leads to reversible immune dysfunction. Nat Med,2006,12(10): 1198-1202.
6 Petrovas C, Casazza JP, Brenchley JM, et al. PD-1 is a regulator of virus-specific CD8+T cell survival inHIV infection. J ExpMed,2006,203(10):2281-2292.
7 Mayer L.Mucosal immunity. Pediatrics,2003,111 (6 Pt3):1595-1600.
8 Das G,Augustine MM,Das J,et al. A important regulatory role for CD4+CD8ααT cells in the intestional epithelial layer in the prevention of inflammatory bowel disease. Proc Natl Acad Sci USA,2003,100 (9):5324-5329.
1 Lombard I,Vincent-Salomon A,Validier,et al Human papillomvirus genotype as a majoy determinant of the course of cervical cancer[J]. Journal of Clinical Oncology,1998,16(8):2613-2619.
2 Franco EL,Duarate-franco E,et al. Cervical cancer:epidemiology, prevention and the role of human papillomavirus infection [J]. CMAJ,2001,164(7):1017-1025.
3 金哲,李云波.消毒栓血清药理对宫颈癌SiHa细胞P53基因调控作用的研究[J].天津中医药,2007,24(1)：47-50.
4 李云渡,金哲.消毒栓含药血清对宫颈癌SiHa细胞MDM2基因的影响[J].中国中西医结合杂志,2007,(27)2：147-150.5楼姣英,金哲,李云波.消毒辁血清药对宫颈癌SiHa细胞凋亡及周期的影响[J].北京中医药.2008,27(7)：563-565.
6金哲,宋爱武,李仁杰.清毒栓治疗宫颈人乳头瘤病毒感染的临床研究.中国中西医结合杂志2002；10(10)：735-737.
7 金哲,楼姣英.清毒栓治疗宫颈人乳头瘤病毒(HPV)亚临床感染地临床研究.中华中西医临床杂志,2006,1(2)：20-22.
8 Stevens MP, Tabrizi SN, Quirm MA, et al. Human papilomavirus genotype prevalence in cervical biopsies from women diagnosed with cervical intraepithelial neoplasia or cervical cancer in Melbourne, Australia[J]. Int J Gynecol Cancer,2006,16(3):1017-1024.
9 Andersson S, Safari H, Mints M, et al. Type distribution, viral load and integration status of high-risk human papillomaviruses in prestages of cervical cancer(CIN). Br J Cancer,2005,92(12):2195-2200.
10 Zhao FH, et al. Associations of high-risk HPV types and viral load with cervical cancer in China. J Clin virol,2006,35:264-269.
11 de Cremoux P, de la Rochefordibre A, Savignoni A, et al. Different outcome of invasive cervical cancer associated with high-risk versus intermediate-risk HPVgenotype. Int J Cancer,2009; 124(4):778-782.
12 M Zerbini, et al. Distribution and viral load of type specific HPVs in different cervical lesion as detected by PCR-EUSA. J. Cain. Path01.2001, 54:377-380.
13 X Castellsague, et al. Chapter 3:Cofactors in human papillomavirus carcinogenesis-role of parity, oral contraceptives, and tobacco smoking. J Nail Cancer Inst Monoger,2003,31:20-28.
14 Chua KL,Wiklund F,Lenner P,et al.Aprospective study on the risk of cervical intraepithelial neoplasia among healthy subjects with serum antibodies to HPV compared with HPVDNA in cervical smears.Int J Cancer,1996,68:54-59.
15 Kaufman RH,Adam E, Icenogle J,et al.Relevance of human papillomavirus screening in management of cervical intraepithelial neoplasia. Am J Obstet Gyneo,1997,176:87-92.
16 A Hildesheim and sS Wang. Host and viral genetics and risk of cervical cancer:a review. Virus Res,2002,89(2):229-240.
17 M Arbyn, et al. Virologic Versus Cytologic Triage of Women With Equivocal PaP Smear:A Meta-analysis of the Accuracy To Detect High-Glade Intraepithelial Neoplasia. J Natl Cancer Inst,2004,96:280-293.
18尚春霞,李红英,尚素霜,张静.奥平-干扰素栓治疗宫颈入乳头瘤病毒亚临床感染的疗效观察.河北医药,2007,29(5)：476-478.
19 Rivera A, Tyring SK. Therapy of cutaneous human papilloma virus infections. Dermatol Ther,2004,17(6):441-448.